New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:12 EDTCGEN, BAYRYCompugen achieves initial milestone in collaboration with Bayer HealthCare
Compugen Ltd. (CGEN) disclosed hat it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first preclinical milestone for one of two checkpoint protein candidates for which Compugen will receive a $1.2M payment out of the $30M potential milestone payments associated with joint preclinical research for the two programs. The collaboration and license agreement provides the framework for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators. Under the terms of the agreement, Bayer and Compugen are jointly pursuing a preclinical research program for each of the two candidates. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Under the terms of the agreement, Compugen has received an upfront payment of $10M and is eligible to receive over $500M in potential milestone payments for both checkpoint programs, plus an additional $30M of potential milestone payments associated with joint preclinical research for the two programs. Compugen is also eligible to receive royalties on global net sales from any resulting products under the collaboration.
News For CGEN;BAYRY From The Last 14 Days
Check below for free stories on CGEN;BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
07:14 EDTBAYRYAmerican Association of Physicists in Medicine to hold annual meeting
56th Annual Meeting of AAPM to be held in Austin, Texas on July 20-25.
July 14, 2014
12:39 EDTCGENCompugen jumps after announcing newly discovered proteins
Compugen (CGEN) is rallying after the company announced earlier today that it has extended discovery capabilities to additional immunomodulatory proteins. WHAT'S NOTABLE: Compugen announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the company’s pipeline program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints. The newly discovered proteins have been added to the company’s pipeline program as potential targets for cancer immunotherapy. Dr. Cohen-Dayag, CEO of Compugen, noted "We are of course very proud that in less than four years, we have established a growing position in this field, including a substantial early-stage pipeline of therapeutic product candidates for both oncology and immunology, based largely on our B7/CD28-like protein candidate discoveries. With today’s announcement, we are further broadening our early-stage pipeline with additional immunomodulatory opportunities and again demonstrating the power and flexibility of our predictive discovery capabilities." PRICE ACTION: In afternoon trading, Compugen 's stock rallied 51c, or almost 6%, to $9.39.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use